Overview

A Randomized, Double-Blind, Placebo-Controlled Study of PIMO to Treat Subjects With GERD

Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 on heartburn symptom-free days in two similar subject groups with GERD-related heartburn symptoms.
Phase:
Phase 2
Details
Lead Sponsor:
Microbiome Health Sciences
Collaborator:
VBHRC Virginia Catalyst